thalidomide has been researched along with Scleritis in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Scleritis: Refers to any inflammation of the sclera including episcleritis, a benign condition affecting only the episclera, which is generally short-lived and easily treated. Classic scleritis, on the other hand, affects deeper tissue and is characterized by higher rates of visual acuity loss and even mortality, particularly in necrotizing form. Its characteristic symptom is severe and general head pain. Scleritis has also been associated with systemic collagen disease. Etiology is unknown but is thought to involve a local immune response. Treatment is difficult and includes administration of anti-inflammatory and immunosuppressive agents such as corticosteroids. Inflammation of the sclera may also be secondary to inflammation of adjacent tissues, such as the conjunctiva.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is an immunomodulatory agent that was approved for the treatment of a monoclonal bone marrow disorders, myelodysplastic syndrome del(5q)(MDS del(5q)), in 2005; the drug was subsequently also approved for the treatment of refractory multiple myeloma, a bone marrow malignancy of the B-lymphocyte lineage." | 5.39 | Can lenalidomide play a role in the management of scleritis? ( Abul, N; Al-Awadhi, A; Al-Jafar, HA; Kumar, N, 2013) |
| "Lenalidomide is an immunomodulatory agent that was approved for the treatment of a monoclonal bone marrow disorders, myelodysplastic syndrome del(5q)(MDS del(5q)), in 2005; the drug was subsequently also approved for the treatment of refractory multiple myeloma, a bone marrow malignancy of the B-lymphocyte lineage." | 1.39 | Can lenalidomide play a role in the management of scleritis? ( Abul, N; Al-Awadhi, A; Al-Jafar, HA; Kumar, N, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Jafar, HA | 1 |
| Abul, N | 1 |
| Kumar, N | 1 |
| Al-Awadhi, A | 1 |
| Huddleston, SM | 1 |
| Houser, KH | 1 |
| Walton, RC | 1 |
2 other studies available for thalidomide and Scleritis
| Article | Year |
|---|---|
Can lenalidomide play a role in the management of scleritis?
Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Scleritis; Thalidomide | 2013 |
Thalidomide for recalcitrant nodular scleritis in sarcoidosis.
Topics: Female; Humans; Immunosuppressive Agents; Middle Aged; Recurrence; Sarcoidosis; Scleritis; Thalidomi | 2014 |